Monoclonal antibodies for treatment of cancer
View Patent ↗The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
1. An isolated antibody having the ability of binding to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 3-10 and 35-79 and mediating inhibition of proliferation of cells expressing a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with the cell surface.
2. The isolated antibody of claim 1 , wherein said inhibition of proliferation of said cells is induced by binding of said antibody to a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells.
3. The isolated antibody of claim 2 , wherein said antibody binds to the extracellular domain of a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells.
4. The isolated antibody of claim 1 , wherein said cells are cancer cells.
5. The isolated antibody of claim 4 , wherein said cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian, liver, colon, pancreatic, esophageal, head-neck, renal, prostate and hepatocellular cancer cells.
6. The isolated antibody of claim 1 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody.
7. The isolated antibody of claim 1 selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.
8. The isolated antibody of claim 7 selected from the group consisting of an IgG2a and IgG2b antibody.
9. The isolated antibody of claim 1 , wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2.
10. The isolated antibody of claim 1 which binds to native epitopes of a protein comprising the amino acid sequence of SEQ ID NO: 2 present on the surface of living cells.
11. The isolated antibody of claim 1 , wherein said protein comprising the amino acid sequence of SEQ ID NO: 2 is expressed on the surface of said cells.
12. A hybridoma or recombinant cell producing the antibody of claim 1 .
13. An antibody produced by the hybridoma or recombinant cell of claim 12 .
14. A conjugate comprising the antibody of claim 1 coupled to a therapeutic agent.
15. The conjugate of claim 14 , wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.
16. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising the antibody of claim 13 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising the conjugate of claim 14 and a pharmaceutically acceptable carrier.